These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30121880)

  • 1. Pharmacological Evaluation of TAK-828F, a Novel Orally Available RORγt Inverse Agonist, on Murine Colitis Model.
    Igaki K; Nakamura Y; Komoike Y; Uga K; Shibata A; Ishimura Y; Yamasaki M; Tsukimi Y; Tsuchimori N
    Inflammation; 2019 Feb; 42(1):91-102. PubMed ID: 30121880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
    Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
    Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological effects of TAK-828F: an orally available RORγt inverse agonist, in mouse colitis model and human blood cells of inflammatory bowel disease.
    Igaki K; Nakamura Y; Tanaka M; Mizuno S; Yoshimatsu Y; Komoike Y; Uga K; Shibata A; Imaichi H; Takayuki S; Ishimura Y; Yamasaki M; Kanai T; Tsukimi Y; Tsuchimori N
    Inflamm Res; 2019 Jun; 68(6):493-509. PubMed ID: 30972425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological evaluation of TAK-828F, a novel orally available RORγt inverse agonist, on murine chronic experimental autoimmune encephalomyelitis model.
    Nakamura Y; Igaki K; Uga K; Shibata A; Yamauchi H; Yamasaki M; Tsuchimori N
    J Neuroimmunol; 2019 Oct; 335():577016. PubMed ID: 31374381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical Properties of TAK-828F, a Potent and Selective Retinoid-Related Orphan Receptor Gamma t Inverse Agonist.
    Nakagawa H; Koyama R; Kamada Y; Ochida A; Kono M; Shirai J; Yamamoto S; Ambrus-Aikelin G; Sang BC; Nakayama M
    Pharmacology; 2018; 102(5-6):244-252. PubMed ID: 30134246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPH7854, a gut-limited RORγt antagonist, ameliorates TNBS-induced experimental colitis in rat.
    Xiang Z; Zhang B; Cao S; Cao L; Li L; Huang D; Li Q; Chen Y; Gong X; Zhang X; Li R; Wu J; Peng Y; Huo G; Xu L; Zhang Z; Li D; Xia G
    Int Immunopharmacol; 2024 Oct; 140():112884. PubMed ID: 39133959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.
    Bassolas-Molina H; Raymond E; Labadia M; Wahle J; Ferrer-Picón E; Panzenbeck M; Zheng J; Harcken C; Hughes R; Turner M; Smith D; Calderón-Gómez E; Esteller M; Carrasco A; Esteve M; Dotti I; Corraliza AM; Masamunt MC; Arajol C; Guardiola J; Ricart E; Nabozny G; Salas A
    Front Immunol; 2018; 9():2307. PubMed ID: 30405600
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of dual GPBAR1 agonist and RORγt inverse agonist for the treatment of inflammatory bowel diseases.
    Biagioli M; Di Giorgio C; Morretta E; Bellini R; Massa C; Urbani G; Bordoni M; Marchianò S; Lachi G; Sepe V; Monti MC; Distrutti E; Zampella A; Fiorucci S
    Pharmacol Res; 2024 Oct; 208():107403. PubMed ID: 39265668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo.
    Skepner J; Ramesh R; Trocha M; Schmidt D; Baloglu E; Lobera M; Carlson T; Hill J; Orband-Miller LA; Barnes A; Boudjelal M; Sundrud M; Ghosh S; Yang J
    J Immunol; 2014 Mar; 192(6):2564-75. PubMed ID: 24516202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asymmetric Synthesis of a 5,6,7,8-Tetrahydro-1,6-naphthyridine Scaffold Leading to Potent Retinoid-Related Orphan Receptor γt Inverse Agonist TAK-828F.
    Tsuruoka R; Yoshikawa N; Konishi T; Yamano M
    J Org Chem; 2020 Aug; 85(16):10797-10805. PubMed ID: 32701287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells suppress development of colitis, blocking differentiation of T-helper 17 into alternative T-helper 1 cells.
    Sujino T; Kanai T; Ono Y; Mikami Y; Hayashi A; Doi T; Matsuoka K; Hisamatsu T; Takaishi H; Ogata H; Yoshimura A; Littman DR; Hibi T
    Gastroenterology; 2011 Sep; 141(3):1014-23. PubMed ID: 21699791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic modulation of RORγt translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis.
    Xue X; Soroosh P; De Leon-Tabaldo A; Luna-Roman R; Sablad M; Rozenkrants N; Yu J; Castro G; Banie H; Fung-Leung WP; Santamaria-Babi L; Schlueter T; Albers M; Leonard K; Budelsky AL; Fourie AM
    Sci Rep; 2016 Dec; 6():37977. PubMed ID: 27905482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonizing Retinoic Acid-Related-Orphan Receptor Gamma Activity Blocks the T Helper 17/Interleukin-17 Pathway Leading to Attenuated Pro-inflammatory Human Keratinocyte and Skin Responses.
    Ecoeur F; Weiss J; Kaupmann K; Hintermann S; Orain D; Guntermann C
    Front Immunol; 2019; 10():577. PubMed ID: 30972071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Inflammatory T Helper Cells
    Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
    Front Immunol; 2018; 9():1138. PubMed ID: 29910804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells' Differentiation and Function in Induction of Colitis.
    Chen L; Sun M; Wu W; Yang W; Huang X; Xiao Y; Ma C; Xu L; Yao S; Liu Z; Cong Y
    Inflamm Bowel Dis; 2019 Aug; 25(9):1450-1461. PubMed ID: 30918945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation.
    Huang XL; Zhang X; Fei XY; Chen ZG; Hao YP; Zhang S; Zhang MM; Yu YQ; Yu CG
    World J Gastroenterol; 2016 Jun; 22(22):5201-10. PubMed ID: 27298563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neomangiferin modulates the Th17/Treg balance and ameliorates colitis in mice.
    Lim SM; Kang GD; Jeong JJ; Choi HS; Kim DH
    Phytomedicine; 2016 Feb; 23(2):131-40. PubMed ID: 26926174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis.
    Jiang XP; Huang XL; Yang ZP; Wang SC; Xie W; Miao L; Tang L; Huang ZM
    Mol Immunol; 2018 Jan; 93():9-19. PubMed ID: 29121519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant suppression of T
    Na H; Lim H; Choi G; Kim BK; Kim SH; Chang YS; Nurieva R; Dong C; Chang SH; Chung Y
    J Allergy Clin Immunol; 2018 Jun; 141(6):2061-2073.e5. PubMed ID: 28943467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.